The Vernakalant Story: How Did It Come to Approval in Europe and What is the Delay in the U.S.A?

Publisher： Bentham Science Publishers

E-ISSN： 1875-6557|10|4|309-314

ISSN： 1573-403X

Source： Current Cardiology Reviews, Vol.10, Iss.4, 2014-11, pp. : 309-314

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Are we at the Goal Line with the Novel Oral Anticoagulants and Have We Reached the End of the Line for Dronedarone and Vernakalant – or is There More to Come?

By  

Current Cardiology Reviews, Vol. 10, Iss. 4, 2014-11 ,pp. : 315-316

Bentham Science Publishers

Access to resources Recommend Favorite

What Is a Good Story?

By Gubrium Jaber  

Generations, Vol. 27, Iss. 3, 2003-09 ,pp. : 21-24

American Society on Aging

Access to resources Recommend Favorite

How Did We Make Transitions Such a Big Deal?

By  

Generations, Vol. 36, Iss. 4, 2012-12 ,pp. : 35-43

American Society on Aging

Access to resources Recommend Favorite

On the benefit of assisted reproduction techniques, a comparison of the USA and Europe

By Nygren K.   Andersen A.Nyboe   Felberbaum R.   Gianaroli L.   de Mouzon J.  

Human Reproduction, Vol. 21, Iss. 8, 2006-08 ,pp. : 2194-2194

Oxford University Press

Access to resources Recommend Favorite

On the benefit of assisted reproduction techniques, a comparison of the USA and Europe

By Gleicher N.   Weghofer A.   Barad D.  

Human Reproduction, Vol. 22, Iss. 2, 2007-02 ,pp. : 624-626

Oxford University Press

Access to resources Recommend Favorite